What are the perceived advantages and disadvantages of non-nucleoside reverse transcriptase inhibitors as first-line therapy?

HIV Medicine

Volumn 1, Issue SUPPL. 1, 2000, Pages 11-14

  Gazzard, B G ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HIV AGENTS; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR;

DRUG COMBINATION; DRUG EFFECT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; REVIEW; TREATMENT OUTCOME; VIROLOGY;

ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMAN; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 18044404926     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1293.2000.00009.x     Document Type: Article

References (20)

1. DannerSA, Carr A, Leonard JM, étal. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-protease. NEngl J Med 1995; 333: 1528-1533.
2. Ingrand D, Weber J, Boucher CA, ft al. Phase I/II study of 3TC (lamivudine) in HIV-positive, asymptomatic or mild AIDSrelated complex patients: sustained reduction in viral markers. The Lamivudine European HIV Working Group. AIDS 1995; 9: 1323-1329.
3. Revicki DA, Moyle G, Stellbrink HJ, Barker C. Quality of life outcomes of combination zalcitabine-zidovudine, saquinavirzidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeter. PISCES (Svl4604) Study Group. AIDS 1999; 7: 13: 851-858.
4. Cameron DW, Heath-Chiozzi M, Danner S, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet 1998; 21: 351: 543-549.
5. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 11: 337: 725-733.
6. Pialoux G, Youle M, Dupont BE, et al. Pharmacokinetics of R 82913 in patients with AIDS or AIDS-related complex. lancer 1991; 20: 338: 140-143.
7. Raboud JM, Rae S, Vella S, étal. Meta-analysis of two randomized controlled trials comparing combined zidovudine and didanosine therapy with combined zidovudine, didanosine, and nevirapine therapy in patients with HFV. INCAS study team. J AIDS 1999; 1: 22: 260-266.
8. Staszewski S, Morales-Ramirez J, Tashima KT. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl JMed 1999; 16:341: 1865-1873.
9. Wood R, Hawkins DA, Moyle G, De Cian W, Ingrosso A, Greenwald C. Second placebo-controlled study in naive individuals confirms the role of delavirdine in higly active antiretroviral, protease-sparing treatment. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 31 January-4 February 1999; 185 (abstract 624).
10. Finzi D, Blankson J, Siliciano JD, eraJ. Latent infection of CD4 T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999; 5: 512-517.
11. Purnell JQ, Zambon A, Knopp RH, et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 2000; 14: 51-57.
12. Rafft F, Saves M, Le Moing V, et al. Serious adverse events (SAE) in a prospective cohort of HIV-infected adults started on protease inhibitor therapy (ANRS EP11 study). 6th Conference on Retroviruses and Opportunistic Infections, Chicago 31 January-4 February 1999; 4: 195 (abstract 676).
13. Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection [editorial]. AIDS 1999; 24: 13: 2493-2505.
14. Moyle G, Baldwin C, Dent N, Gazzard B. Management of indinavir-associated metabolic changes by substitution with efavirenz in virologically controlled HIV+ persons. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 31 January-4 February, 1999; 4: 193 abstract 669.
15. Martin C, Sönnerborg A, Svensson JO, Stähle L. Indinavirbased treatment of HIV-1 infected patients: efficacy in the central nervous system. AIDS 1999; 13: 1227-1232.
16. Bower M, Fox P, Fife K, Gill J, Nelson M, Gazzard B. Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma. AIDS 1999; 13: 2105-2111.
17. Nelson M, Stàszewski S, Morales-Ramirez J étal. Successful virologie suppression with efavirenz in HIV-infected patients with low baseline CD4 cell counts: post hoc results from study 006. 10th European Congress of Clinical Diseases, Stockholm, May 2000; abstract 3-349.
18. Dybul M, Chun T-W, Ward D, eraJ. Evaluation of lymph node virus burden in human immunodeficiency virusinfected patients receiving efavirenz-based protease inhibitor-sparing highly active antiretroviral therapy. J Infect Dis 2000; 181: 1273-1279.
19. Autran B, Carcelain G, Li TS, eraJ. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997; 277: 112-116.
20. Sullivan A, Nelson M, Moyle G, et al. Immune responses in patients changing from PI to NNRTI based HAART. 6th Annual Conference of the British HIV Association (BHIVA), Edinburgh, March 2000; 17 (Abstract P43).